









Markets
/
Stocks
/
nasdaq-dmac
/

DiaMedica Therapeutics Inc

DMAC

6.760USD

-0.110-1.60%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

291.17MMarket Cap

LossP/E TTM



DiaMedica Therapeutics Inc

6.760

-0.110-1.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

93 / 507

Overall Ranking

208 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+76.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 78.74.

Undervalued

The company’s latest PE is -9.90, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 25.51M shares, increasing 9.85% quarter-over-quarter.

Held by Leon Cooperman

Star Investor Leon Cooperman holds 1.65M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.96.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.46, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.46

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -9.90, which is -37.19% below the recent high of -6.22 and 9.19% above the recent low of -8.99.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 93/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for DiaMedica Therapeutics Inc is 12.00, with a high of 14.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+79.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

DiaMedica Therapeutics Inc

DMAC

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 9.30, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 7.86 and the support level at 5.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.42

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.002

Neutral

RSI(14)

61.229

Neutral

STOCH(KDJ)(9,3,3)

47.531

Sell

ATR(14)

0.478

High Vlolatility

CCI(14)

30.157

Neutral

Williams %R

31.061

Buy

TRIX(12,20)

1.283

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

6.940

Sell

MA10

6.962

Sell

MA20

6.363

Buy

MA50

5.401

Buy

MA100

4.678

Buy

MA200

4.977

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 59.66%, representing a quarter-over-quarter increase of 1.77%. The largest institutional shareholder is Leon Cooperman, holding a total of 1.65M shares, representing 3.19% of shares outstanding, with 15.89% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

EQT Partners AB

5.53M

Trill AB,LLC.

5.22M

Jacinto (Richard II)

4.56M

B. Riley Asset Management, LLC

2.21M

Omega Advisors, Inc.

Star Investors

1.63M

The Vanguard Group, Inc.

Star Investors

1.35M

+8.80%

Paragon JV Partners, LLC

600.00K

+16.55%

Geode Capital Management, L.L.C.

315.74K

+3.27%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.32, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.